Abstract
Heart failure (HF) remains a leading cause of morbidity, mortality, and healthcare expenditures. A surge in novel technologies targeting different components of chronic HF pathophysiology has emerged, including the CardioMEMS pulmonary artery pressure monitor, the carotid barostimulator (Barostim Neo™) and the Bodyport cardiac scale. Despite the growing availability of remote solutions, the limited availability of robust studies has led to lower-level recommendations by national cardiology societies which may limit their adoption. One way to generate practical application data is by integrating established real-time hemodynamic monitoring devices with novel innovations, providing real-world evidence to support emerging solutions. In this case series, we review remote patient monitoring tools and their ability to evaluate novel implanted cardiovascular devices. This study aims to illustrate the benefit of clinical integration of these technologies and advocate for further use of this approach to enhance their real-world applicability in patient care.